Alternative names
MDBP
IUPAC Name
1-(benzo[1,3]dioxol-5-ylmethyl)piperazine
Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Discussion
1-(3,4-Methylenedioxybenzyl)piperazine (MDBP or MDBZP) is a piperazine derivative but its effects are largely unknown. MDBP has never been licensed as a medicine but is a metabolite of a withdrawn nootropic medicine, fipexide. This medicine was withdrawn because it had adverse toxic effects (fever and hepatotoxicity). Use of MDBP has been noted by governmental organizations in the United States but there are no reports from other countries. There are no published reports of non-fatal or fatal hospital admissions. No specific studies have been performed to determine the abuse or dependence potential of MDBP.
Recommendation
Based on the lack of animal, human clinical, and epidemiological data on the abuse and dependence potential of MDBP, the Expert Committee did not recommend a critical review of 1-(3,4-methylene-dioxybenzyl) piperazine at this time.
1-(3,4-Methylenedioxybenzyl)piperazine (MDBP or MDBZP) is a piperazine derivative but its effects are largely unknown. MDBP has never been licensed as a medicine but is a metabolite of a withdrawn nootropic medicine, fipexide. This medicine was withdrawn because it had adverse toxic effects (fever and hepatotoxicity). Use of MDBP has been noted by governmental organizations in the United States but there are no reports from other countries. There are no published reports of non-fatal or fatal hospital admissions. No specific studies have been performed to determine the abuse or dependence potential of MDBP.
Recommendation
Based on the lack of animal, human clinical, and epidemiological data on the abuse and dependence potential of MDBP, the Expert Committee did not recommend a critical review of 1-(3,4-methylene-dioxybenzyl) piperazine at this time.
ECDD Recommendation
No change in scheduling
Link to full TRS
who_trs_973_eng.pdf1.73 MB
MS Questionnaire Report